Fluorescence optical imaging in pediatric patients with inflammatory and non-inflammatory joint diseases: a comparative study with ultrasonography

Marisa Christin Beck1,2*, Anne-Marie Glimm2, Sarah Ohndorf2, Kirsten Minden1,2, Ralf Trauzeddel3, Stephanie Gabriele Werner4, Gerd Horneff5, Marina Backhaus2,6, Gerd Rüdiger Burmester2, Tilmann Kallinich7, Hermann Girshick8† and Jens Klotsche1,9†

Abstract

Background: Valid detection of arthritis is essential in differential diagnosis of joint pain. Indocyanin green (ICG)-enhanced fluorescence optical imaging (FOI) is a new imaging method that visualizes inflammation in wrist and finger joints. Objectives of this study were to compare FOI with ultrasonography (US, by gray-scale (GS) and power Doppler (PD)) and clinical examination (CE) and to estimate the predictive power of FOI for discrimination between inflammatory and non-inflammatory juvenile joint diseases.

Methods: FOI and GSUS/PDUS were performed in both hands of 76 patients with joint pain (53 with juvenile idiopathic arthritis (JIA), 23 with non-inflammatory joint diseases). Inflammation was graded by a semiquantitative score (grades 0–3) for each imaging method. Joints were defined clinically active if swollen or tender with limited range of motion. Sensitivity and specificity of FOI in three phases dependent on ICG enhancement (P1–P3) were analyzed with CE and GSUS/PDUS as reference.

Results: For JIA patients, FOI had an overall sensitivity of 67.3%/72.0% and a specificity of 65.0%/58.8% with GSUS/PDUS as reference; specificity was highest in P3 (GSUS 94.3%/PDUS 91.7%). FOI was more sensitive for detecting clinically active joints than GSUS/PDUS (75.2% vs 57.3%/32.5%). In patients with non-inflammatory joint diseases both FOI and US showed positive (i.e., pathological) findings (25% and 14% of joints). The predictive value for discrimination between inflammatory and non-inflammatory joint diseases was 0.79 for FOI and 0.80/0.85 for GSUS/PDUS.

Conclusions: Dependent on the phase evaluated, FOI had moderate to good agreement with CE and US. Both imaging methods revealed limitations and should be interpreted cautiously. FOI may provide an additional diagnostic method in pediatric rheumatology.

Trial registration: Deutsches Register Klinischer Studien DRKS00012572. Registered 31 July 2017.

Keywords: Juvenile idiopathic arthritis, Arthralgia, Imaging, Fluorescence optical imaging, Ultrasound, Power Doppler

* Correspondence: marisa.beck@charite.de
† Equal contributors
1German Rheumatism Research Center, a Leibniz Institute, Program Area Epidemiology, Charitéplatz 1, 10117 Berlin, Germany
2Charité University Medicine Berlin, Rheumatology and Clinical Immunology, Charitéplatz 1, 10117 Berlin, Germany
3Rheumazentrum Surgical Consultation, Berlin, Germany
4Universitätsklinikum Schleswig-Holstein, Departments of Clinical Immunology and Rheumatology, Kiel, Germany
5Max Planck Institute for Molecular Genetics, Berlin, Germany
6Charité University Medicine Berlin, Charité Campus Benjamin Franklin, Department of Rheumatology and Clinical Immunology, Charitéplatz 1, 10117 Berlin, Germany
7Rheumazentrum Berlin-Buch, Berlin, Germany
8Medizinische Universität Graz, Institute for Rheumatology, Graz, Austria
9Biomedical Imaging and Innovation Center, Charité University Medicine Berlin, Charitéplatz 1, 10117 Berlin, Germany

© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Joint pain is a common complaint in children and adolescents, about 10–20% of school children being affected [1–3]. Distinguishing inflammatory from non-inflammatory causes is an important diagnostic step, but can be challenging. Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease in childhood and requires early and adequate anti-inflammatory treatment [4, 5] as it may lead to permanent joint damage and functional disability [6–8]. Non-inflammatory causes of joint pain like idiopathic pain syndromes may require other modes of treatment in an interdisciplinary therapeutic approach [9].

The current International League of Associations for Rheumatology (ILAR) classification criteria of JIA and its treatment strategies and prognosis are, among other criteria, based on the number of inflamed joints involved (<5 vs ≥ 5, oligoarthritis vs polyarthritis) [4, 10], and therefore accurate detection of arthritis in any joint is essential. However, sensitive detection by clinical examination (CE) alone can be difficult, especially in cases of mild arthritis. Ultrasonography (US) in gray-scale (GS) and in power Doppler mode (PD) are established imaging tools for both the detection of synovitis and estimation of current arthritis activity; both techniques have been shown to be more sensitive than CE [11–13]. US allows an immediate, safe, and inexpensive evaluation and is well suited for children. However, it is known to have a relatively high observer dependency [14]. Magnetic resonance imaging (MRI) is regarded as the gold standard for assessment of arthritis in both adults and children [15–18]. However, discrimination between pathological and age-related physiological changes in children and adolescents proves to be problematic [19]. Because of further disadvantages such as high costs, long duration of examination, and the possible need for sedation in younger children, it is not routinely performed in the pediatric rheumatology outpatient clinic.

Indocyanin green (ICG)-enhanced fluorescence optical imaging (FOI) is a novel technology utilizing near-infrared light to visualize altered microcirculation (e.g., neoangiogenesis, hyperperfusion, and capillary leakage) in inflamed joints of the hands and wrists [20, 21]. Advantages of the method are the possibility of examining all joints of both hands (30 joints) together in a relatively short time period (6 minutes), its standardized setting, and the lack of ionizing radiation. However, the application of an intravenous (IV) contrast agent (ICG) might be disadvantageous, although possible side effects are rarely seen.

Comprehensive validation studies on adult patients with different arthritis have shown good agreement of FOI with GSUS, PDUS, and MRI as well as variable sensitivity and specificity dependent on FOI phase and joint, by comparison [22–24]. These results cannot be simply transferred to children and adolescents as the altered vascularity of the juvenile cartilage and growth-related changes might affect the imaging. There are few data regarding its use in pediatric patients, yet first examinations of children by FOI were promising and the examination was well tolerated [25–27].

Our study was designed to determine the association and agreement of FOI with US (GSUS, PDUS) findings and physician assessment of clinical arthritis severity in joints of symptomatic children, as well as to estimate the predictive power of FOI to distinguish between inflammatory juvenile rheumatic diseases and non-inflammatory arthralgia.

Methods

A total of 76 patients from three pediatric rheumatology centers in Berlin, Germany were recruited for this observational study. The patients were consecutively included. Inclusion criteria were joint pain (due to present JIA or without known reason), age of 6–18 years, and agreement of patient and parents. Exclusion criteria were allergy against ICG or iodine, hyperthyroidism, pregnancy, breast feeding, other known severe diseases, and chronic or active infection of the hands.

The patients were categorized into three groups: group I included 29 JIA patients with clinically relevant active arthritis in the hand region at the time of examination (as determined by pediatric rheumatologist); group II included 23 patients with arthralgia (e.g., caused by hypermobility syndrome, juvenile fibromyalgia, or other arthralgia without inflammatory character); and group III consisted of 53 JIA patients regardless of disease activity and affection of the hand region at the time of examination, and included all patients from group I. All JIA patients included fulfilled the ILAR criteria [10]. In patients with new onset of symptoms and/or uncertain diagnosis at the time of examination, the diagnoses were reconfirmed approximately 1 year later.

The study was performed in compliance with the Declaration of Helsinki. The study protocol was approved by the local ethics committee of the Charité University Medicine Berlin, Germany (No. EA2/126/12). Written informed consent was obtained from all participants.

Clinical and laboratory examinations

For each patient, a detailed CE was performed in all 71 joints. Joints were defined as clinically active by the presence of either joint swelling or tenderness and limited range of motion. The assessment included a physician’s global disease activity score by a 21-point numerical rating scale (NRS), patient’s/parent’s global assessment of overall well-being by the same 21-point NRS, and an assessment of the patient’s functional capacity by the Childhood Health Assessment Questionnaire (CHAQ)
score [28]. The clinical Juvenile Arthritis Disease Activity Score (cJADAS10, range 0–30), which counts any involved joint to a maximum of 10 joints, was calculated for JIA patients [29]. The erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were determined for 65 and 71 patients respectively as part of their routine examinations.

Musculoskeletal ultrasonography

Ultrasonographic examination of both hands was performed in a neutral position by gray-scale (GSUS) and power Doppler (PDUS) ultrasound with the following two machines and settings: Mylab Twice (Esaote, Genova), GSUS 16-MHz frequency, linear probe and PDUS 9.1-MHz frequency, 750-Hz pulse repetition frequency (PRF); and Philips HD15, GSUS 12-MHz frequency, linear probe and PDUS 5.5-MHz frequency, 600-Hz PRF.

The wrist, the interphalangeal joint of the thumb (IP), and the metacarpophalangeal (MCP I–V), proximal (PIP II–V), and distal interphalangeal (DIP II–V) joints were examined and scored semiquantitatively for presence of synovial thickening or joint effusion (combined as synovitis) in GSUS (0 = absent, 1 = mild, 2 = moderate, 3 = marked) and hyperperfusion in PDUS (0 = absent, 1 = presence of up to three single color signals or one confluent signal indicating hyperperfusion, 2 = perfusion signals in less than half of the synovial/joint area, 3 = perfusion signal exceeding half or more than half of the joint) [11].

GSUS and PDUS were analyzed blinded to the clinical characteristics of the patient. For evaluation of interreader agreement between the two pediatric centers conducting sonographic examinations, a random sample survey of 11 static GSUS and PDUS images was taken from patients from center 1 and scored independently by the center 2 pediatric rheumatologist.

Fluorescence optical imaging

FOI was performed in each patient with the Xiralite® X4 system (Mivenion, Berlin, Germany) following a standardized procedure [22]. Standard examination time was 6 minutes, recording one image per second and hence adding up to a sequence of 360 images. A bolus of ICG with a dose of 0.1 mg/kg body weight was injected as an IV dye 10 seconds after the beginning of image acquisition. For interpretation, both film modus and an automatically generated composite image (Prima Vista Mode (PVM)) were considered. Evaluation was carried out according to Werner et al. [22, 23], who defined three phases of the film modus (P1, P2, P3) based on signal intensity in the fingertips. P1 describes the time between starting the examination and presentation of increased signal intensities in the fingertips, P2 is defined as the phase with persisting high signal intensities in the fingertips, and P3 begins with the absence of signal intensity in the fingertips and lasts until the end of examination (see Fig. 1). Each joint was scored semiquantitatively by color intensity, size, and shape of enhancement from grades 0 to 3 (0 = no signal enhancement, 1 = low signal enhancement (≤25% of affected joint area), 2 = moderate signal enhancement (>25 to ≤50% of affected joint area), 3 = strong signal (≥50% of affected joint area)). For each patient the fluorescence optical imaging activity score (FOIAS) was calculated as a sum score over all joints. All FOI findings were analyzed in consensus by two readers who were blinded to the clinical characteristics of the patient (A-MG, MCB).

Statistical analyses

Data management and statistical analysis were performed using SAS 9.3 (SAS Institute, Cary, NC, USA). Statistical analyses were performed on the patient and individual joint levels. The predictive value for discrimination between patients with inflammatory and non-inflammatory joint diseases by CE, GSUS, PDUS, and FOI was evaluated by calculating the area under receiver operating characteristics curve (AUC). The correlation of CE, GSUS, PDUS, and FOI scores was estimated by the standardized regression coefficient from univariable linear regression analyses. The standardized regression coefficient is reported as a measure

![Fig. 1 FOI findings in a patient with arthralgia (group II) without signs of inflammation. P1 describes the period between starting the examination and increased signal intensities in the fingertips, the time point of increased signal intensity in the fingertips is analyzed for evaluation. P2 is defined as the phase with persisting high signal intensities in the fingertips, the time point of a red-colored signal in the fingertips is analyzed for evaluation. P3 begins with the absence of signal intensity in the fingertips, and the time point of a missing (no) signal in the fingertips is analyzed for evaluation. PVM automatically generated Prima Vista Mode, P1–P3 phases 1–3](image-url)
of association and can be interpreted as the correlation. A robust variance estimator was used to account for the possible correlation of CE, GSUS, PDUS, FOI, and CE within the study sites [30]. A sum score of the gradings across the 30 hand joints of a patient was considered for the analyses on the patient level. Likewise, the association of the different methods was analyzed on the joint level. Agreement rates were determined at the individual joint level taking into consideration all evaluated joints. In each imaging method, a joint was considered to be affected if its grading was greater than or equal to one (grade ≥ 1) and otherwise to be unaffected (grade 0, normal). CE, GSUS, and PDUS were used as reference methods for determining the absolute agreement, sensitivity, and specificity between various pairs of modalities. In order to investigate possible growth-related changes of FOI during the pubertal growth spurt (i.e., increased vascularization leading to more positive FOI results), we further divided groups I and II into patients aged < 13 and patients aged ≥ 13 and analyzed the respective distribution of the FOI sum scores. Besides, interreader agreement was evaluated by the kappa statistics. \( p < 0.05 \) was considered statistically significant.

**Results**

**Group I**

**Study population**

Twenty-nine JIA patients with clinically relevant active arthritis in the hand region were included in this group. Mean age at examination was 13.7 years (standard deviation (SD) = 3.3, median = 14.0); mean number of joints with clinically active arthritis in the hand region was 7.1 (SD = 5.2). Clinical parameters at study enrolment are presented in detail in Table 1.

**Comparison of CE, US, and FOI**

FOI findings were compared with US findings (Figs. 2 and 3) and clinical findings in 870 wrist and finger joints.

Prevalence of joints with pathological findings was 206 (24%), 281 (32%), 118 (14%), and 395 (45%) by CE, GSUS, PDUS, and FOI, respectively. Most frequently affected joints in each method were the wrists as well as PIP joints. In FOI, the largest number of increased signal intensities was found in P2 (34% of joints). The number of joints with grading ≥ 2 was 87 (10%) in GSUS, 27 (3%) in PDUS, and 233 (26.8%) in FOI.

The age-related distribution of FOI scores showed no relevant differences between patients aged < 13 and patients aged ≥ 13 years (Fig. 4).

**Sensitivity and specificity**

Of the 206 joints rated as clinically active, 57.3%/32.5% were also positive by GSUS/PDUS and 75.2% by FOI. Of the 664 non-inflamed joints by CE, 75.5%/92.3% was negative in GSUS/PDUS and 63.9% was negative in FOI. With CE as reference, FOI sensitivity was highest in P2 (62.6%) and specificity was highest in P3 (93.1%).

Taking GSUS as reference, CE had a sensitivity of 42.0% and a specificity of 85.1% and FOI had a sensitivity of 67.3% and a specificity of 65.0%. With PDUS as reference, CE had a sensitivity of 56.8% and a specificity of 81.5% while FOI had a sensitivity of 72.0% and a specificity of 58.8%. Specificity of FOI compared to US was high in PVM and P3 (GSUS 86.9% and 94.3%; PDUS 84.8% and 91.7%). However, corresponding sensitivities were low (GSUS 28.1% and 18.6%; PDUS 35.6% and 20.3%). Sensitivity of FOI was highest in P1 (GSUS 51.8%; PDUS 59.8%) (Table 2).

**Agreement rates**

Agreement of CE and US (GSUS and/or PDUS) was 71.6%. Agreement of CE and FOI ranged from 71.8 to 78.2% depending on the individual phases of FOI, agreement of GSUS and FOI ranged from 66.7 to 70.5%, and agreement of PDUS and FOI ranged from 67.9 to 81.9%. Highest agreement was found for P3 where mostly negative results were present, the lowest was found for P2 (Table 2). Lack of accordance was primarily due to a higher proportion of positive findings by FOI; in 16.8% of joints only FOI was rated positive. US and FOI consistently detected abnormal findings in 47.6% of clinically active joints and in 14.2% of clinically inactive joints.

**Group II**

**Study population**

Twenty-three patients with arthralgia without any known inflammatory rheumatic disease were included in this group. None showed signs of clinical inflammation in any joint region. Mean age at examination was 13.8 years (SD = 2.4, median = 14.9); mean number of joints with arthralgia in the hand region was 5.2 (SD = 7.9). Clinical parameters are presented in detail in Table 1.

**Comparison of CE, US, and FOI**

Figure 1 shows a typical FOI image sequence of a patient with arthralgia but without any increased signal intensity as a sign of inflammation in any phase.

Of the 690 wrists and finger joints evaluated, none had clinical signs of arthritis. However, 17 patients showed abnormalities in GSUS and/or PDUS suggestive of inflammatory activity in 96 joints (14%) (GSUS 94 joints, PDUS 13 joints), and 21 patients showed increased signal intensities in FOI in 172 joints (25%). The number of joints with grading ≥ 2 was 17 (2.4%) in GSUS, one (0.1%) in PDUS, and 53 (7.7%) in FOI. In FOI, P2 showed most increased signal intensities (16.8%), whereas P3 showed least signals and thus was most specific (98.2%). In US, most positive results were found...
|                        | Group I: JIA patients with clinically active arthritis in the hand region (n = 29) | Group II: non-inflammatory joint diseases (n = 23) | Group III: all JIA patients (n = 53) |
|------------------------|----------------------------------------------------------------------------------|-------------------------------------------------|------------------------------------|
| Gender                 |                                                                                  |                                                 |                                    |
| Female                 | 23 (79)                                                                         | 19 (83)                                         | 45 (85)                            |
| Male                   | 6 (21)                                                                          | 4 (17)                                          | 8 (15)                             |
| Age (years), median    | 13.7 (3.3); 14.0                                                               | 13.8 (2.4); 14.9                               | 13.7 (3.3); 14.1                   |
| Disease duration (years), median | 3.3 (4.0); 1.6                   | 1.7 (1.8); 1.1                                | 3.7 (4.1); 2.1                     |
| Diagnosis              |                                                                                  |                                                 |                                    |
| Juvenile idiopathic arthritis | 29 (100.0)                        | n.a.                                            | 53 (100.0)                         |
| Systemic arthritis     | 0 (0.0)                                                                         | n.a.                                            | 1 (2)                              |
| Oligoarthritis, persistent | 0 (0.0)                          | n.a.                                            | 6 (11)                             |
| Oligoarthritis, extended | 0 (0.0)                           | n.a.                                            | 1 (2)                              |
| Polyarthritis, seronegative | 19 (66)                          | n.a.                                            | 28 (53)                            |
| Polyarthritis, seropositive | 5 (17)                           | n.a.                                            | 7 (13)                             |
| Enthesitis-related arthritis | 2 (7)                            | n.a.                                            | 6 (11)                             |
| Psoriatic arthritis    | 2 (7)                                                                          | n.a.                                            | 3 (6)                              |
| Other arthritis        | 1 (3)                                                                          | n.a.                                            | 1 (2)                              |
| Arthralgia             | n.a.                                                                            | n.a.                                            | 23 (100)                           |
| Physician’s global assessment (NRS 0–10) |                                                                                  |                                                 |                                    |
| Mean (SD)              | 3.4 (1.9)                                                                       | n.a.                                            | 2.4 (1.9)                          |
| Inactive disease (NRS < 1) | 0 (0.0)                          | n.a.                                            | 9 (17)                             |
| Therapy                |                                                                                  |                                                 |                                    |
| Nonsteroidal anti-inflammatory drugs | 20 (69)                           | 10 (43.5)                                       | 31 (59)                            |
| Systemic glucocorticoids, low dose | 5 (17)                           | 0 (0.0)                                         | 6 (11)                             |
| Systemic glucocorticoids, high dose | 3 (10)                           | 0 (0.0)                                         | 3 (6)                              |
| Disease-modifying antirheumatic drugs | 19 (65)                           | 0 (0.0)                                         | 32 (60)                            |
| Methotrexate           | 15 (52)                                                                         | 0 (0.0)                                         | 23 (43)                            |
| Sulphasalazine         | 2 (7)                                                                           | 0 (0.0)                                         | 3 (6)                              |
| Leflunomide            | 1 (3)                                                                           | 0 (0.0)                                         | 1 (2)                              |
| Etanercept             | 4 (14)                                                                          | 0 (0.0)                                         | 6 (11)                             |
| Adalimumab             | 0 (0.0)                                                                         | 0 (0.0)                                         | 3 (6)                              |
| Abatacept              | 1 (3)                                                                           | 0 (0.0)                                         | 1 (2)                              |
| Tocilizumab            | 2 (7)                                                                           | 0 (0.0)                                         | 2 (4)                              |
| Canakinumab            | 1 (3)                                                                           | 0 (0.0)                                         | 1 (2)                              |
| ESR (mm/h), mean (SD); n | 17.0 (19.2); 24                    | 9.5 (6.5); 21                                  | 14.8 (16.1); 44                    |
| CRP (mg/dl), mean (SD); n | 0.4 (0.5); 28                     | 0.1 (0.1); 23                                  | 0.3 (0.5); 48                      |
| cJADAS-10              |                                                                                  |                                                 |                                    |
| Mean (SD)              | 13.3 (4.8)                                                                      | n.a.                                            | 9.5 (5.9)                          |
| Inactive disease (cJADAS-10 ≤ 1) | 0 (0.0)                          | n.a.                                            | 3 (6)                              |
| CHAQ                   |                                                                                  |                                                 |                                    |
| Mean (SD)              | 0.7 (0.6)                                                                       | 0.5 (0.6)                                       | 0.5 (0.6)                          |
| No functional disability (CHAQ = 0) | 7 (24)                           | 8 (27)                                          | 16 (30)                            |
| Patient’s Global Assessment (NRS 0–10), mean (SD) | 2.6 (2.2)                           | 3.9 (3.4)                                       | 2.6 (2.2)                          |

JIA juvenile idiopathic arthritis, SD standard deviation, n.a. not applicable, NRS numerical rating scale, ESR erythrocyte sedimentation rate, CRP C-reactive protein, cJADAS clinical Juvenile Arthritis Disease Activity Score, CHAQ Childhood Health Assessment Questionnaire
in the wrists and MCP joints, and in FOI most positive results were found in the wrists and PIP joints.

Again, the age-related distribution of FOI scores showed no relevant differences between patients aged < 13 and patients aged ≥ 13 years (Fig. 4).

**Sensitivity, specificity, and agreement rates of US and FOI**

Agreement of US and FOI was high, given the fact that most results were expected to be negative. With both GSUS and PDUS as reference, FOI had specificity up to 98.6% (in P3, respectively). However, overall sensitivity was relatively low (GSUS 39.4%; PDUS 61.5%). In 5.5% of joints both imaging methods showed positive findings.

**Groups I and II: predictive value of FOI, GSUS/PDUS, and diagnosis and their correlations**

The predictive value for discrimination between inflammatory and non-inflammatory rheumatic diseases was calculated. The area under the curve (95% CI) was 0.85 (0.75–0.95) for PDUS, 0.80 (0.68–0.92) for GSUS, and 0.79 (0.67–0.91) for any FOI phase (P2 = 0.77 (0.64–0.89)).

On the patient level, correlation of US with joints with clinically active arthritis was strong (GSUS, $\beta = 0.63$ ($p < 0.001$); PDUS, $\beta = 0.69$ ($p < 0.001$)), whereas correlation of FOI with clinically active arthritis was moderate ($\beta = 0.32$–0.54 ($p < 0.001$)). Correlation of FOI with US was moderate. P1 was found to correlate most strongly with GSUS ($\beta = 0.50$ ($p < 0.001$) and P2 with PDUS ($\beta = 0.51$ ($p < 0.001$)) (Table 3). On the joint level, correlation of US with clinically active joints was moderate (GSUS, $\beta = 0.37$ ($p < 0.001$); PDUS, $\beta = 0.35$ ($p > 0.001$)), as well as correlation of FOI with clinically active joints (up to $\beta = 0.40$ ($p < 0.001$) for any FOI phase). Correlation of FOI with GSUS was weak to moderate (up to $\beta = 0.35$ ($p < 0.001$) in P2); there was no correlation between FOI and PDUS on the joint level (Table 4).

**Group III**

**Study population**

This group consisted of 53 JIA patients with variable current disease activity in the hand region, and included all 29 patients of group 1. Mean age at examination was 13.7 years (SD = 3.3, median = 14.1); mean number of joints with arthritis in the hand region was 4.1 (SD = 5.1). Clinical parameters are presented in detail in Table 1.

**Findings in CE, US, and FOI**

Of 1590 joints evaluated, 218 (13.7%) were classified as clinically active. US was positive in 26% and FOI in 41.3% of all joints examined.

**Correlations of FOI and US with clinical and functional parameter of disease activity**

Synovitis scores and FOIAS were compared with the cJADAS10, physician’s global assessment of disease activity, functional disability scores (CHAQ), and laboratory parameters (ESR, CRP) (Table 5). Correlation between GSUS/PDUS and cJADAS10 was found to be
relevant \((\beta = 0.62 \ (p < 0.001))/\beta = 0.66 \ (p < 0.001)\), as well as correlation with physician's global assessment of disease activity \((\beta = 0.51 \ (p < 0.001))/\beta = 0.55 \ (p < 0.001)\). There was a weak correlation between GSUS/PDUS and CHAQ \((\beta = 0.32 \ (p = 0.018))/\beta = 0.36 \ (p = 0.008)\) and no correlation with the patient-reported outcome measurements of pain and fatigue. GSUS/PDUS and inflammatory blood parameters did not show any correlation.

Correlation between FOIAS and cJADAS10 was moderate \((P2, \beta = 0.42 \ (p = 0.002))\), as well as correlations with physician's global assessment of disease activity \((P2, \beta = 0.38 \ (p = 0.005))\). FOI PVM correlated moderately with CRP level \((\beta = 0.48 \ (p = 0.0001))\). There was no correlation between FOIAS and CHAQ or between FOIAS and patient-reported outcome measurements of pain and fatigue.

**Interreader agreement for ultrasonography**

Interreader agreement was investigated in 11 static GSUS and PDUS images between two blinded independent raters. Interreader agreement was found to be good for GSUS (agreement in 93% of joints, \(\kappa = 0.76\)) and substantial for PDUS (agreement in 100% of joints, \(\kappa = 1.00\)), when considering the number of joints with any positive signal. The agreement rate for the grading was slightly lower for GSUS (agreement in 60% of joints, \(\kappa = 0.61\)) and PDUS (agreement in 66% of joints, \(\kappa = 0.70\)). The highest proportion of disagreement was found between grading 1 and 2 (GSUS, 20% of joints; PDUS, 26% of joints).

**Safety**

In all subjects, the procedure was well tolerated. One patient presented circulatory problems due to peripheral

|                       | FOI | CE   | GSUS | PDUS |
|-----------------------|-----|------|------|------|
| Group I: JIA with clinically active arthritis in the hand region |     |      |      |      |
| FOI any phase         | 66.6| 75.2 | 63.9 | 65.7 |
| PVM                   | 78.2| 41.7 | 89.5 | 67.9 |
| P1                    | 72.3| 56.3 | 77.2 | 70.5 |
| P2                    | 71.8| 62.6 | 74.7 | 66.7 |
| P3                    | 75.3| 19.4 | 93.1 | 69.5 |
| CE                    | –   | –    | –    | 71.1 |
| GSUS                  | 71.1| 57.3 | 75.5 | –    |
| PDUS                  | 78.2| 32.5 | 92.3 | 80.3 |
|                       |     |      |      |      |
| Group II: non-inflammatory joint diseases |     |      |      |      |
| FOI any phase         | 75.0| 0.0  | 75.0 | 72.1 |
| PVM                   | 93.3| 0.0  | 93.3 | 84.6 |
| P1                    | 88.0| 0.0  | 88.0 | 80.1 |
| P2                    | 83.2| 0.0  | 83.2 | 77.1 |
| P3                    | 98.2| 0.0  | 98.2 | 86.0 |
| CE                    | –   | –    | –    | 86.4 |
| GSUS                  | 86.4| 0.0  | 86.4 | –    |
| PDUS                  | 98.1| 0.0  | 98.1 | 87.7 |

FOI fluorescence optical imaging, CE clinical examination (joints with clinically active arthritis), GSUS ultrasonography in gray-scale mode, PDUS ultrasonography in power Doppler mode, JIA juvenile idiopathic arthritis, PVM Prima Vista Mode, P1–P3 FOI phases 1–3
Table 3 Group I and II: correlation of FOI, GSUS/PDUS, and CE on the patient level; standardized β (p value)

|                  | Number of joints with active arthritis | GSUS   | PDUS   |
|------------------|----------------------------------------|--------|--------|
| FOI any phase    | 0.54 (<0.001)                          | 0.48 (<0.001) | 0.43 (0.001) |
| PVM              | 0.45 (0.001)                           | 0.38 (0.006) | 0.43 (0.001) |
| P1               | 0.52 (<0.001)                          | 0.50 (<0.001) | 0.38 (0.006) |
| P2               | 0.54 (<0.001)                          | 0.45 (0.001) | 0.51 (<0.001) |
| P3               | 0.32 (0.020)                           | 0.46 (0.001) | 0.43 (0.002) |
| GSUS             | 0.63 (<0.001)                          | –      | –      |
| PDUS             | 0.69 (<0.001)                          | –      | –      |

FOI fluorescence optical imaging, CE clinical examination (joints with clinically active arthritis), GSUS ultrasonography in gray-scale mode, PDUS ultrasonography in power Doppler mode, PVM Prima Vista Mode, P1–P3 FOI phases 1–3

Table 4 Group I and II: correlation of FOI, GSUS/PDUS, and CE on the joint level; standardized β (p value)

|                  | Joints with active arthritis | GSUS   | PDUS   |
|------------------|-----------------------------|--------|--------|
| FOI any phase    | 0.40 (<0.001)              | 0.35 (<0.001) | 0.29 (0.001) |
| PVM              | 0.35 (0.001)               | 0.23 (0.006) | 0.20 (0.001) |
| P1               | 0.36 (<0.001)              | 0.35 (<0.001) | 0.27 (0.006) |
| P2               | 0.36 (<0.001)              | 0.30 (0.001) | 0.25 (<0.001) |
| P3               | 0.23 (0.020)               | 0.23 (0.001) | 0.19 (0.002) |
| GSUS             | 0.37 (<0.001)              | –      | –      |
| PDUS             | 0.35 (<0.001)              | –      | –      |

FOI fluorescence optical imaging, CE clinical examination (joints with clinically active arthritis), GSUS ultrasonography in gray-scale mode, PDUS ultrasonography in power Doppler mode, PVM Prima Vista Mode, P1–P3 FOI phases 1–3

IV insertion before the fluorescent compound was applied. The FOI examination could be performed after recovery. No adverse events were observed.

Discussion
ICG-enhanced FOI with the Xiralite® system is a novel imaging technique that has been shown to visualize inflammation in arthritis of wrist and finger joints and has been evaluated in various validation studies in adult rheumatology [22–24]. The aim of this study was to acquire data regarding the use of FOI in children and adolescents with joint diseases by comparing it to findings in both sonographic and CE.

Patients with juvenile idiopathic arthritis
Consistent with previous studies in adults [22–24], FOI showed a higher rate of positive findings than the other compared modalities. Most signals were found in P2, which was also the most sensitive phase compared to CE (62.6%). This supports the hypothesis that it might be the most valuable phase for detecting subclinical activity [22–24]. However, there is a need for further evaluation to prove this.

Agreement of FOI and CE was comparable to agreement of GSUS/PDUS and CE, whereas FOI overall sensitivity for detecting clinically active arthritis was higher than GSUS/PDUS sensitivity (75.2% vs 57.3%/32.5%).

Agreement of FOI and US was good, especially agreement with PDUS (up to 81.9%), which reflects the fact that both FOI and PDUS display acute inflammatory changes rather than chronic changes. Sensitivity of FOI compared to US was moderate. The highest values were reached if increased signal intensities in any phase were considered (GSUS 67.3%, PDUS 72.0%). Analyzing the phases separately, highest sensitivity was found for FOI P1 compared to hyperperfusion in PDUS in JIA patients with clinically active arthritis (59.8%) with corresponding high specificity (74.0%). This supports the theory by Werner et al. [22] that P1 reflects high synovial vascularization and thus correlates best with disease activity [33]. However, these results distinguish from results of previous studies comparing FOI to US which found P2 to be the most sensitive phase [22–24].

In accordance with adult studies, highest specificity compared to both GSUS and PDUS was found for P3 (94.3% and 91.7%). This was the phase showing least signal intensity increase; presumably it reflects increased capillary permeability with abnormal persistency of ICG and is therefore mostly found positive in osteoarthritis [22, 23, 34].

Differences in the characteristics of the FOI phases compared to previous studies might result from the higher variation of ICG distribution patterns we observed in children and adolescents compared to adults. Defining the phases according to the standardized protocol was difficult in several cases, where the ICG distribution deviated from the known characteristic flow behavior. This is possibly due to growth-related vascular changes and might have had an influence on sensitivity and agreement rates of the individual phases. Therefore, the current standard of interpretation in adult rheumatology by Werner et al. [22, 23]—in particular the definitions of the phases—might have to be reevaluated for pediatric rheumatology. This could also be concluded by means of the moderate correlations of US and FOI scores on the joint and patient levels (Tables 3 and 4). We found no relevant differences in the distribution of FOIAS scores between patients aged < 13 years and patients aged ≥ 13 years (see Fig. 4). Nevertheless, further age-related examinations are needed for evaluation of growth-related changes in FOI.

Both FOI and US detected a high number of positive results in clinically asymptomatic joints of JIA patients. In adult rheumatology, it is known that residual synovitis in patients with rheumatoid arthritis in clinical remission is frequent and predicts the risk of relapse and ongoing structural joint damage [35]. Even though there are follow-up reports suggesting that subclinical arthritis detected by US also predicts development of clinical
arthritus in JIA patients [36], direct evidence from comparing US to histopathological findings—as has been provided for adults—has not been (and most likely will not be) tested for children. Pre/post comparisons of adult patients with inflammatory arthritis in clinical remission suggested that positive signals in FOI in clinically asymptomatic joints may also predict a relapse after premature withdrawal of treatment [37]. A recent study found FOI to be particularly sensitive in detecting clinically silent inflammation in joints that were positive by US [31].

In our study, agreement of US and FOI in clinically inactive joints that presented abnormalities in imaging was relatively low (up to 25.4%), showing that such preclinical/subclinical findings in children and adolescents have to be interpreted with caution. After all, validity of US in pediatric rheumatology has still not been fully established and preliminary standardized definitions of synovitis in US were established only recently [38]. Additionally, it is known that there is a wide range of growth-related variations in joints of children and adolescents that can be seen on imaging. In MRI studies of patients with JIA, changes in bone shape, signal intensity, and the amount of joint fluid were found that were partly unrelated to disease activity [39]. Moreover, bony depressions resembling erosions are frequently seen on MRI of healthy children [19]. Therefore, the clinical importance of such findings in both MRI and FOI remains to be determined and it is unclear whether FOI findings in asymptomatic joints of JIA patients demonstrate subclinical inflammation and thus predict development of clinically apparent arthritis. In the future, follow-up studies could help in evaluating their significance.

Patients with arthralgia without any known inflammatory rheumatic disease
This group served as a control group, because none of the patients presented clinical signs of an inflammatory joint disease. Previous examinations of healthy controls and individuals with arthralgia without any sign of inflammatory rheumatic disease showed a low rate of positive findings in FOI (0–5%) [22, 23]. However, a vast majority of 91% of this group had increased signal enhancements in at least one joint and phase. Also, 74% of the patients showed abnormalities in US suggestive of synovitis.

Remarkably, there was only moderate agreement between the positive results detected by US and FOI, suggesting that the mechanisms causing such findings differ between the two techniques. This is most likely due to the fact that FOI is based on different physical principles than US, such as light optics and microangiography. Thus, it should be considered a complementary rather than a competitive imaging method.

The high number of positive signals in both US and FOI resulted from many joints being scored grade 1. Excluding those joints greatly minimized positive results and led to high specificities (FOI 94.5–99.2%, US 97.4%). For clinical use, this could mean that FOI tends to overestimate findings and that discreet findings with scores < 2, especially in P2, should be interpreted with caution in children with suspected inflammatory rheumatic diseases, as they might not be a sign of active arthritis but of mechanical stress or blood flow alterations. As discussed before, this possibility should also be considered for patients with inflammatory diseases with positive signals in clinically inactive joints. However, any finding in P3 should be taken seriously, as this highly specific phase might reflect the presence of inflammation.

Most positive results in both US and FOI in patients with non-inflammatory diseases were found in the wrists. Interestingly, these results are compatible with observations in a healthy control group whose wrists were examined by MRI, where a high prevalence of increased volumes of joint fluid, signal changes similar to bone marrow edema, and bony depressions resembling erosions were found [19]. Both MRI and FOI findings might reflect mechanical stress through the high use of this part of the hand during daily activity.

The predictive value for discrimination between active inflammatory and non-inflammatory conditions was calculated. We found it to be comparably high for both GSUS/PDUS and FOI (0.80/0.85 and 0.79) with slight advantages for US, showing that they are equally valid methods for differential diagnosis in children and adolescents with unclear joint pain.

Limitations
Our study has some limitations. Specific limitations of the technology include the lack of visualization of

### Table 5: Group III: correlation of FOI, GSUS, and PDUS with clinical parameters; β (p value)

|                        | GSUS     | PDUS     | FOI any phase | PVM     | P1       | P2       | P3       |
|------------------------|----------|----------|---------------|---------|----------|----------|----------|
| Physician’s assessment | 0.51 (<0.001) | 0.55 (<0.001) | 0.37 (0.007) | 0.37 (0.006) | 0.36 (0.008) | 0.38 (0.005) | 0.29 (0.034) |
| Number of joints with arthritis | 0.59 (<0.001) | 0.63 (<0.001) | 0.39 (0.004) | 0.36 (0.008) | 0.36 (0.008) | 0.46 (<0.001) | 0.30 (0.028) |
| cJADAS-10              | 0.62 (<0.001) | 0.66 (<0.001) | 0.36 (0.008) | 0.36 (0.008) | 0.34 (0.013) | 0.42 (0.002) | 0.37 (0.007) |
| CHAQ score             | 0.32 (0.019) | 0.36 (0.008) | 0.10 (0.471) | 0.22 (0.106) | 0.12 (0.388) | 0.21 (0.127) | 0.17 (0.238) |

FOI: fluorescence optical imaging, GSUS: ultrasonography in gray-scale mode, PDUS: ultrasonography in power Doppler mode, PVM: Prima Vista Mode, P1–P3: FOI phases 1–3, cJADAS: clinical Juvenile Arthritis Disease Activity Score, CHAQ: Childhood Health Assessment Questionnaire.
anatomic structures as well as the limited ability to assess palmar inflammation due to overlying structures reducing the depth of light penetration, most notably in the area of MCP joints. Also, FOI is currently available for examination of hands and wrists only, whereas the most common category of JIA—oligoarthritis—is often manifest in the knee or ankle joint. Therefore, the method might be more valuable for polyarticular-course JIA. Furthermore, it is limited to older children as the method’s fixed setup requires the patient’s capability to keep still for 6 minutes as well as a minimum arm’s length. The youngest patient examined in our study was 6.5 years old.

FOI demonstrates any inflammation of the hand region including scratches or psoriatic plaques, which can result in signal enhancement similar to synovitis. Even though experienced readers are able to identify signals caused by such skin lesions, any clinical findings should be documented in order to be considered in image interpretation [40].

FOI is a procedure that includes an IV injection with potential side effects, like circulatory problems and allergic reactions. In our study, FOI examination was tolerated well, with one report of circulatory problems due to peripheral IV insertion before the fluorescent compound was applied.

The study population was rather inhomogeneous including several patients with unclear clinical findings at the time of examination. In hindsight, this limitation could be reduced by verifying every patient’s diagnosis approximately 1 year after the examination. Another limitation was the use of two different US machines with potential variance in resolution and display.

Ultimately, we were confronted with the problem that there is no assured gold standard for detection of synovitis in children, which is why sensitivities and specificities should be regarded with reserve. Because of the fact that MRI is an invasive technique and not a routine procedure in pediatric rheumatology, we were not able to include it as a reference method in our study.

Conclusions
ICG-enhanced FOI is a new imaging technique in rheumatology. It detects and excludes inflammatory changes in joints of children and adolescents in good agreement with sonography and CE.

FOI had the highest rate of positive findings of all methods and showed signal enhancements in a majority of patients without known inflammatory rheumatic diseases, which is why discreet findings should always be put in a clinical context. Sonographic examination also showed limitations, proving that despite its value in clinical routine it cannot be regarded as an assured standard of reference in pediatric rheumatology. After all, both diagnostic methods need to be interpreted with caution in the use of children in order not to overestimate their findings. Diagnosis of patients with unclear clinical findings remains challenging. However, FOI is a simple, non-ionizing, and well-tolerated method that could serve as an additional diagnostic tool in pediatric rheumatology. In order to further evaluate the value of this method, and particularly its subclinical findings, more studies in pediatric rheumatology are needed.

Abbreviations
AUC: Area under receiver operating characteristics curve; CE: Clinical examination; CHAQ: Childhood Health Assessment Questionnaire; cJADAS: Clinical Juvenile Arthritis Disease Activity Score; CRP: C-reactive protein; DIP: Distal interphalangeal; ESR: Erythrocyte sedimentation rate; FOI: Fluorescence optical imaging; FOIAS: Fluorescence optical imaging activity score; GS: Gray-scale mode; ICG: Indocyanin green; ILAR: International League of Associations for Rheumatology; IP: Interphalangeal; IV: Intravenous; JIA: Juvenile idiopathic arthritis; MCP: Metacarpophalangeal; MRI: Magnetic resonance imaging; NRS: Numerical rating scale; P: Phase; PD: Power Doppler mode; PIP: Proximal interphalangeal; PMV: Prima Vista Mode; PRF: Pulse repetition frequency; SD: Standard deviation; US: Ultrasonography

Acknowledgements
The authors thank all patients and their parents for participating in this study. They thank Gabriela Schmittar, Stefanie Bartsch, and Kathleen Necke for technical and organizational support.

Funding
This study was funded by an unconditional grant from Pfizer Pharma GmbH, Berlin. There was no role of the funding body in the design of the study, in collection, analysis, and interpretation of data, or in writing the manuscript.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
Substantial contributions to study conception and design, and substantial contribution to analysis and interpretation of data have been given by all coauthors (MCB, A-MG, SO, KM, RT, SGW, GH, MB, GRB, TK, HG, JK). JK analyzed the data and provided statistical support. MCB, A-MG, and SGW read the fluorescence optical images. MCB, KM, TK, RT, HG, SO, A-MG, and MB performed examinations and data collection at the respective centers. MCB wrote the manuscript and all coauthors contributed substantially to it. All coauthors read and approved the final manuscript.

Ethics approval and consent to participate
The study was performed in compliance with the Declaration of Helsinki. The study protocol was approved by the local ethics committee of the Charité University Medicine Berlin, Germany (No. EA2/126/12). All study participants were informed about the examination process, risks, and potential side effects of the fluorescence dye. Written informed consent was obtained from all participants.

Consent for publication
By signing informed consent, the participations in this study (patients and parents) approved the use of their pseudonymized data for scientific analysis.

Competing interests
MCB, A-MG, SO, RT, SGW, MB, GRB, TK, HG, and JK declare that they have no competing interests. KM has received honoraria for lectures from Pfizer, Roche, and Pharm-Allergan. GH has received grants and honorary fees from Abbvie, Pfizer, Novartis, and Roche/Chugai.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1German Rheumatism Research Center, a Leibniz Institute, Program Area Epidemiology, Charitéplatz 1, 10117 Berlin, Germany. 2Charité University Medicine Berlin, Rheumatology and Clinical Immunology, Charitéplatz 1,
References

1. Haas J. Chronische musculoskeletale Schmerzen bei Kindern und Jugendlichen. Monatschr Kinderheilkd. 2009;157:647–54.
2. King S, Chambers CT, Huguet A, Machnevc RC, McGrath PJ, Parker L. Macdonald AJ. The epidemiology of chronic pain in children and adolescents: revisited: a systematic review. Pain. 2011;152:2729–38.
3. Goodman JE, McGrath PJ. The epidemiology of pain in children and adolescents: a review. Pain. 1991;54:267–44.
4. Klein A, Horneff G. Treatment strategies for juvenile idiopathic arthritis. Expert Opin Pharmacother. 2009;10:3039–60.
5. Minden K, Niewerth M, Zink A, Meineke E, Seipelt E, Foeldvari I, Girschick H, Ganser G, Münzel T, Scharfetter-Kochanek K. Long-term outcome of patients with juvenile rheumatoid arthritis treated with etanercept results of the biologic register JUMBO. Rheumatology (Oxford). 2012;51:1407–15.
6. Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schöntube M, Zink A, Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46:2392–401.
7. Oen K, Malleson PN, Cabral DA, Rosenberg AM, Cheang M, Disease course and outcome of juvenile rheumatoid arthritis in a multicenter cohort. J Rheumatol. 2002;29:1989–99.
8. Oen K, Reed M, Malleson PN, Cabral DA, Petty RE, Cheang M, Radiologic outcome and its relationship to functional disability in juvenile rheumatoid arthritis. J Rheumatol. 2003;30:812–20.
9. Hechler T, Martin A, Blankenburg M, Schroeder K, Kosfelder J, Holscher L, Denecke H, Zernikow B. Specialized multimodal outpatient treatment for children with chronic pain: treatment pathways and long-term outcome. Eur J Pain. 2011;15:976–84.
10. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Pireur AM, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.
11. Magni-Manzoni S, Epsz P, Ravelli A, Kleer K, Vincoort C, Lanz I, Muratore V, Scire CA, Rossi S, Montecucco C. Comparison of clinical versus ultrasound-determined synovitis in juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:1497–504.
12. Backhaus M, Kamradt T, Sandrock D, Loreck D, Fritz J, Wolf KJ, Raber H, Harm B, Burmester GR, Bollow M. Arthritis of the finger joints: a comprehensive approach comparing conventional radiography, scintigraphy, ultrasound, and contrast-enhanced magnetic resonance imaging. Arthritis Rheum. 1999;42:1232–45.
13. Janow GL, Panghaal V, Trinh A, Badger D, Levin TL, Iwlowe NT. Detection of active disease in juvenile idiopathic arthritis: sensitivity and specificity of the physical examination vs ultrasound. J Rheumatol. 2011;38:2671–4.
14. Scheel AK, Schmidt WA, Hermann KG, Bruyn GA, D‘Agostino MA, Grass W, Iagnocco A, Koski JM, Machold KP, Naredo E, et al. Interobserver reliability of rheumatologists performing musculoskeletal ultrasound: results from an EULAR “Train the trainers” course. Ann Rheum Dis. 2005;64:1043–9.
15. Lamer S, Sebag GH, MRI and ultrasound in children with juvenile chronic arthritis. Eur J Radiol. 2000;33:85–93.
16. Miettic M, Malleson PN, Martin A, Tomà P. Synovial and inflammatory diseases in childhood: role of new imaging modalities in the assessment of patients with juvenile idiopathic arthritis. Pediatr Radiol. 2010;40:985–93.
17. Brown AK, Quinn MA, Karim Z, Conaghan PG, Peterfy CG, Hensor E, Wakefield RJ, O'Connor PJ, Emery P. Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum. 2006;54:3761–73.
18. Hoving JL, Buchbinder R, Hall S, Lawler G, Coombes P, McNealy S, Bird P, Connell D. A comparison of magnetic resonance imaging, sonography, and radiography of the hand in patients with early rheumatoid arthritis. J Rheumatol. 2004;31:663–7.
19. Müller LS, Avenarius D, Damasio B, Eidevik OP, Malattia C, Lambot-Juhan K, Tanturi L, Owens CM, Rosendahl K. The radiographic wrist revisited: redefining MR findings in healthy children. Ann Rheum Dis. 2011;70:605–10.
20. Gompels M, Lim NH, Vincent T, Paleolog EM. In vivo optical imaging in arthritis—an enlightening future? Rheumatology (Oxford). 2010;49:1436–46.
21. Bremer C, Werner S, Lange H. Assessing activity of rheumatoid arthritis with fluorescence optical imaging. Eur Musculoskeletal Rev. 2009;4:96–100.
22. Werner SG, Langer HE, Ohndorf S, Bahner M, Schwenke C, Schierl M, Bastian H, Lind-Albrecht G, Kurtz B, et al. Inflammation assessment in patients with arthritis using a novel in vivo fluorescence optical imaging technology. Ann Rheum Dis. 2012;71:504–10.
23. Werner SG, Langer HE, Schott P, Bahner M, Schwenke C, Lind-Albrecht G, Spiecker F, Kurtz B, Burmester GR, Backhaus M. Indocyanine green-enhanced fluorescence optical imaging in patients with early and very early arthritis: a comparative study with magnetic resonance imaging. Arthritis Rheum. 2013;65:3036–44.
24. Krohn M, Ohndorf S, Werner SG, Schicke B, Burmester GR, Hoff M, Backhaus M, Hermann KG. Near-infrared fluorescence optical imaging in early rheumatoid arthritis: a comparison to magnetic resonance imaging and ultrasonography. J Rheumatol. 2015;42:1112–8.
25. Werner SG, Langer HE, Horneff G. Fluorescence optical imaging of juvenile arthritis. J Rheumatol. 2011;38:1447.
26. Horneff G, Werner SG, Langer HE, Backhaus M. Fluoreszenzoptisches Bildgebungssystem Xiralite® zur Einschätzung der Therapieeffizienz bei JIA. Arthritis Rheuma. 2012;71:42–46.
27. Klein A, Just GW, Werner SG, Dornen PT, Minden K, Becker I, Langer HE, Klee D, Horneff G. Fluorescence optical imaging and musculoskeletal ultrasonography in juvenile idiopathic polyarticular disease before and during antirheumatic treatment—a multicenter non-interventional diagnostic evaluation. Arthritis Res Ther. 2017;19:1417.
28. Foeldvari I, Ruperto N, Dressler F, Häßler R, Küster RM, Michels H, Minden K, Schaeren-Petrovskaja C, Bullinger M, Langgraf JW, et al. The German version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in rheumatologic disorders: diagnostic performance of optical imaging technology. Ann Rheum Dis. 2012;71:221–33.
29. Consolaro A, Ruperto N, Basso A, Pistorio A, Magni-Manzoni S, Filocamo G, Malattia C, Viola S, Martini A, Ravelli A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:1658–66.
30. Huber PJ. The behavior of maximum likelihood estimates under nonstandard conditions. In: Vol. 1 of Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability. Berkeley, University of California Press: 1967:121–233.
31. Kisten Y, Győri N, Al Klint E, Rezaei H, Levitsky A, Karlsson A, van Vollenhoven R. Detection of clinically manifest and silent synovitis in the hands and wrists by fluorescent optical imaging. RMD Open. 2015;1:e000106.
32. Meier R, Thieme K, Moor P, Nolte PB, Ahari C, Sievert M, Dohr F, Waldt S, Scheiffele C, Golovko D, et al. Detection of synovitis in the hands of patients with rheumatologic disorders: diagnostic performance of optical imaging in comparison with magnetic resonance imaging. Arthritis Rheum. 2012;64:2489–98.
33. Skudlarek M, Court-Payen M, Strandberg C, Klarlund M, Klausen T, Ostergaard M. Power Doppler ultrasonography for assessment of synovitis in the metacarpophalangeal joints of patients with rheumatoid arthritis: a comparison with dynamic magnetic resonance imaging. Arthritis Rheum. 2001;44:2018–23.
34. Glirim AM, Werner SG, Burmester GR, Backhaus M, Ohndorf S. Analysis of distribution and severity of inflammation in patients with osteoarthritis compared to rheumatoid arthritis by K-G enhanced fluorescence optical imaging and musculoskeletal ultrasound: a pilot study. Ann Rheum Dis. 2010;69:506–10.
35. Nguyen H, Ruyssen-Witrand A, Gandjbakhch F, Constantin A, Foltz V, Cantagrel A. Prevalence of ultrasound-detected residual synovitis and risk of relapse and structural progression in rheumatoid arthritis patients in clinical remission: a systematic review and meta-analysis. Rheumatology (Oxford). 2014;53:2110–8.
36. Nielsen HE, Strandberg C, Andersen S, Kinnander C, Erichsen G. Ultrasonographic examination in juvenile idiopathic arthritis is better than clinical examination for identification of intraarticular disease. Dan Med J. 2013;60:A4669.

37. Werner S, Specker F, Hermann C, et al. ICG-enhanced fluorescence optical imaging in clinical remission: longitudinal data in RA and PSA patients with pre/post comparisons (Abstract). Ann Rheum Dis. 2013;71:605.

38. Roth J, Ravagnani V, Backhaus M, Balzent A, Bruyn GA, Collado P, de la Cruz L, Guillaume-Czitrom S, Herlin T, et al. Preliminary definitions for the sonographic features of synovitis in children. Arthritis Care Res (Hoboken). 2017;69:1217–1223.

39. Ording Muller LS, Boavida P, Avenarius D, Damasio B, Eldevik OP, Malattia C, Lambot-Juhan K, Tanturi L, Owens CM, Roosdahl K. MRI of the wrist in juvenile idiopathic arthritis: erosions or normal variants? A prospective case-control study. Pediatr Radiol. 2013;43:785–95.

40. Finsterer S, Moog P, Meier R, Thümel K. A novel arthritis in vivo fluorescence optical imaging technology pushed to the limits continued-unravelling the signals: quantitative analysis does not distinguish inflammatory skin lesions from active synovitis. Rheumatology (Oxford). 2016;55:1912–4.